What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive repeated subcutaneous doses of CM551 solution in a dose escalation format across 2 sequential MAD cohorts.”In the company’s words, NCT07900945 on ClinicalTrials.gov
- Main trialPhase 1
- “This is a randomized, double-blind, placebo-parallel controlled phase I study to evaluate the safety and tolerability of single and multiple doses of CM551 in healthy participants”In the company’s words, NCT07900945 on ClinicalTrials.gov
Other drugs for Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
- ObefazimodAbivax S.A. · Phase 3
- TofacitinibPfizer · Phase 3
- RisankizumabAbbVie · Phase 3
- UpadacitinibAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
Coming up1
- Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Sep 2027 | Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026